دورية أكاديمية
أعرض في EDS

Development of nitroalkene-based inhibitors to target STING-dependent inflammation.

التفاصيل البيبلوغرافية
العنوان: Development of nitroalkene-based inhibitors to target STING-dependent inflammation.
المؤلفون: Chang F; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, 15213, USA., Gunderstofte C; Department of Biomedicine, Aarhus University, 8000, Aarhus C, Denmark., Colussi N; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, 15213, USA., Pitts M; Department of Physiology, Morehouse School of Medicine, Atlanta, GA, 30310, USA., Salvatore SR; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, 15213, USA., Thielke AL; Department of Biomedicine, Aarhus University, 8000, Aarhus C, Denmark., Turell L; Laboratorio de Enzimología, Instituto de Química Biológica, Facultad de Ciencias, Universidad de la República, Montevideo, 11400, Uruguay; Centro de Investigaciones Biomédicas (CEINBIO), Universidad de la República, Montevideo, 11800, Uruguay., Alvarez B; Laboratorio de Enzimología, Instituto de Química Biológica, Facultad de Ciencias, Universidad de la República, Montevideo, 11400, Uruguay; Centro de Investigaciones Biomédicas (CEINBIO), Universidad de la República, Montevideo, 11800, Uruguay., Goldbach-Mansky R; Translational Autoinflammatory Disease Studies Unit, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, 20850, USA., Villacorta L; Department of Physiology, Morehouse School of Medicine, Atlanta, GA, 30310, USA. Electronic address: lvillacortaperez@msm.edu., Holm CK; Department of Biomedicine, Aarhus University, 8000, Aarhus C, Denmark. Electronic address: holm@biomed.au.dk., Schopfer FJ; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, 15213, USA; Pittsburgh Heart, Lung, Blood, And Vascular Medicine Institute (VMI), Pittsburgh, PA, USA; Pittsburgh Liver Research Center (PLRC), Pittsburgh, PA, USA; Center for Metabolism and Mitochondrial Medicine (C3M), Pittsburgh, PA, USA. Electronic address: fjschopfer@katz.pitt.edu., Hansen AL; Department of Biomedicine, Aarhus University, 8000, Aarhus C, Denmark. Electronic address: annelouisehansen@biomed.au.dk.
المصدر: Redox biology [Redox Biol] 2024 Aug; Vol. 74, pp. 103202. Date of Electronic Publication: 2024 May 21.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier, B.V Country of Publication: Netherlands NLM ID: 101605639 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-2317 (Electronic) Linking ISSN: 22132317 NLM ISO Abbreviation: Redox Biol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Amsterdam]: Elsevier, B.V., [2013]-
مواضيع طبية MeSH: Membrane Proteins*/antagonists & inhibitors , Membrane Proteins*/metabolism , Inflammation*/drug therapy , Alkenes*/chemistry , Alkenes*/pharmacology , Nitro Compounds*/chemistry , Nitro Compounds*/pharmacology, Animals ; Humans ; Mice ; Structure-Activity Relationship
مستخلص: Stimulator of Interferon Genes (STING) is essential for the inflammatory response to cytosolic DNA. Despite that aberrant activation of STING is linked to an increasing number of inflammatory diseases, the development of inhibitors has been challenging, with no compounds in the pipeline beyond the preclinical stage. We previously identified endogenous nitrated fatty acids as novel reversible STING inhibitors. With the aim of improving the specificity and efficacy of these compounds, we developed and tested a library of nitroalkene-based compounds for in vitro and in vivo STING inhibition. The structure-activity relationship study revealed a robustly improved electrophilicity and reduced degrees of freedom of nitroalkenes by conjugation with an aromatic moiety. The lead compounds CP-36 and CP-45, featuring a β-nitrostyrene moiety, potently inhibited STING activity in vitro and relieved STING-dependent inflammation in vivo. This validates the potential for nitroalkene compounds as drug candidates for STING modulation to treat STING-driven inflammatory diseases, providing new robust leads for preclinical development.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Francisco J Schopfer reports a relationship with Creegh Pharmaceuticals Inc that includes: board membership and equity or stocks. Francisco J Schopfer & Fei Chang reports a relationship with Furanica Inc that includes: board membership and equity or stocks. Christian K Holm reports a relationship with UV Medico that includes: consulting or advisory and employment. Francisco J Schopfer, Fei Chang, Christian K Holm, Anne Louise Hansen, Sonia R Salvatore, Luis Villacorta are the inventors of a patent application related to the subject matter of this manuscript. The University of Pittsburgh is the lead institution for this patent application, with joint ownership also held by Aarhus University and Morehouse School of Medicine. Other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
References: Cell Host Microbe. 2015 Aug 12;18(2):157-68. (PMID: 26235147)
Nature. 2019 Mar;567(7747):262-266. (PMID: 30842662)
J Biol Chem. 2017 Jan 27;292(4):1145-1159. (PMID: 27923813)
J Clin Immunol. 2021 Apr;41(3):501-514. (PMID: 33532887)
J Pharmacol Exp Ther. 2019 Jun;369(3):503-510. (PMID: 30894457)
Free Radic Biol Med. 2010 Feb 15;48(4):499-505. (PMID: 19932165)
Proc Natl Acad Sci U S A. 2023 Aug 15;120(33):e2305420120. (PMID: 37549268)
Proc Natl Acad Sci U S A. 2009 May 26;106(21):8653-8. (PMID: 19433799)
J Lipid Res. 2013 Jul;54(7):1998-2009. (PMID: 23620137)
Cell. 2020 Aug 20;182(4):1009-1026.e29. (PMID: 32730809)
Nat Immunol. 2020 Aug;21(8):868-879. (PMID: 32690950)
Immunity. 2019 Jan 15;50(1):64-76.e4. (PMID: 30635240)
Cell. 2019 Jul 11;178(2):290-301.e10. (PMID: 31230712)
J Lipid Res. 2019 Feb;60(2):388-399. (PMID: 30545956)
Immunity. 2008 Oct 17;29(4):538-50. (PMID: 18818105)
Nat Immunol. 2019 Feb;20(2):152-162. (PMID: 30643259)
J Clin Invest. 2014 Dec;124(12):5516-20. (PMID: 25401470)
Sci Adv. 2022 Jul;8(26):eabm9138. (PMID: 35767602)
Nat Commun. 2016 Jun 21;7:11932. (PMID: 27324217)
Immunity. 2006 Jan;24(1):93-103. (PMID: 16413926)
Free Radic Biol Med. 2021 Jan;162:327-337. (PMID: 33131723)
Cell Rep. 2019 Apr 23;27(4):1165-1175.e5. (PMID: 31018131)
Cell Mol Immunol. 2019 Mar;16(3):236-241. (PMID: 30796349)
Nat Rev Immunol. 2021 Sep;21(9):548-569. (PMID: 33833439)
J Virol. 2014 May;88(10):5328-41. (PMID: 24600004)
Science. 2015 Mar 13;347(6227):aaa2630. (PMID: 25636800)
Trends Endocrinol Metab. 2019 Aug;30(8):505-519. (PMID: 31196614)
Nature. 2013 Jun 20;498(7454):380-4. (PMID: 23722158)
N Engl J Med. 2014 Aug 7;371(6):507-518. (PMID: 25029335)
Cell Rep. 2013 May 30;3(5):1355-61. (PMID: 23707065)
Front Pediatr. 2020 Dec 17;8:577918. (PMID: 33425809)
Life Sci Alliance. 2019 Jun 20;2(3):. (PMID: 31221625)
Rheumatol Immunol Res. 2021 Dec 15;2(3):173-184. (PMID: 36465073)
Clin Transl Sci. 2019 Nov;12(6):667-676. (PMID: 31343124)
J Biol Chem. 2013 Aug 30;288(35):25626-25637. (PMID: 23878198)
Sci Rep. 2018 Feb 2;8(1):2295. (PMID: 29396403)
Cell. 2013 Aug 15;154(4):748-62. (PMID: 23910378)
Br J Pharmacol. 2021 Dec;178(24):4907-4922. (PMID: 34460100)
Nat Struct Mol Biol. 2012 Jun 24;19(7):722-4. (PMID: 22728658)
Proc Natl Acad Sci U S A. 2018 Aug 14;115(33):E7768-E7775. (PMID: 30061387)
Nat Struct Mol Biol. 2012 Jun 24;19(7):728-30. (PMID: 22728659)
Nat Struct Mol Biol. 2012 Jun 24;19(7):725-7. (PMID: 22728660)
Cardiovasc Res. 2010 Jan 1;85(1):155-66. (PMID: 19666678)
BMC Immunol. 2021 Dec 17;22(1):77. (PMID: 34920714)
Proc Natl Acad Sci U S A. 2015 Apr 21;112(16):5117-22. (PMID: 25848017)
Cardiovasc Res. 2013 Apr 1;98(1):116-24. (PMID: 23334216)
Nature. 2019 May;569(7758):718-722. (PMID: 31118511)
Cell. 2013 May 23;153(5):1094-107. (PMID: 23647843)
Anal Bioanal Chem. 2002 Jul;373(4-5):266-76. (PMID: 12110978)
J Allergy Clin Immunol. 2017 Aug;140(2):543-552.e5. (PMID: 28087229)
J Biol Chem. 2012 Dec 28;287(53):44071-82. (PMID: 23144452)
Free Radic Biol Med. 2018 Feb 1;115:31-42. (PMID: 29132974)
Food Chem. 2024 Mar 30;437(Pt 1):137767. (PMID: 37879157)
Nature. 2009 Oct 8;461(7265):788-92. (PMID: 19776740)
Science. 2013 Feb 15;339(6121):786-91. (PMID: 23258413)
Science. 2013 Feb 15;339(6121):826-30. (PMID: 23258412)
Proc Natl Acad Sci U S A. 2016 Jun 14;113(24):E3403-12. (PMID: 27302953)
Immunity. 2012 Jun 29;36(6):1073-86. (PMID: 22579474)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
Sci Rep. 2017 Jan 05;7:39900. (PMID: 28054588)
J Exp Med. 2020 Nov 2;217(11):. (PMID: 32725126)
J Biol Chem. 2007 Oct 19;282(42):31085-93. (PMID: 17720974)
Sci Signal. 2012 Mar 06;5(214):ra20. (PMID: 22394562)
Redox Biol. 2018 May;15:522-531. (PMID: 29413964)
J Biol Chem. 2006 Nov 24;281(47):35686-98. (PMID: 16887803)
J Biol Chem. 2010 Apr 16;285(16):12321-33. (PMID: 20097754)
Mol Cell Biol. 2004 Aug;24(15):6719-27. (PMID: 15254239)
Mucosal Immunol. 2018 May;11(3):820-834. (PMID: 29346345)
PLoS Pathog. 2018 Apr 2;14(4):e1006976. (PMID: 29608601)
Trends Neurosci. 2021 Feb;44(2):83-96. (PMID: 33187730)
Nature. 2018 Jul;559(7713):269-273. (PMID: 29973723)
Mol Cell. 2013 Jul 25;51(2):226-35. (PMID: 23747010)
Free Radic Biol Med. 2015 Dec;89:333-41. (PMID: 26385079)
Nature. 2008 Oct 2;455(7213):674-8. (PMID: 18724357)
Mol Cell Biol. 2008 Aug;28(16):5014-26. (PMID: 18559423)
Cell. 2008 Aug 22;134(4):587-98. (PMID: 18724932)
Nature. 2019 Mar;567(7748):394-398. (PMID: 30842653)
Sci Rep. 2018 Aug 24;8(1):12784. (PMID: 30143727)
معلومات مُعتمدة: R01 HL123333 United States HL NHLBI NIH HHS
فهرسة مساهمة: Keywords: Drug discovery; Interferon; Nitroalkene-based compounds; STING inhibitors; STING-associated vasculopathy with onset in infancy (SAVI); Stimulator of Interferon Genes (STING)
المشرفين على المادة: 0 (Membrane Proteins)
0 (Alkenes)
0 (Nitro Compounds)
0 (STING1 protein, human)
تواريخ الأحداث: Date Created: 20240612 Date Completed: 20240617 Latest Revision: 20240919
رمز التحديث: 20240919
مُعرف محوري في PubMed: PMC11215336
DOI: 10.1016/j.redox.2024.103202
PMID: 38865901
قاعدة البيانات: MEDLINE
الوصف
تدمد:2213-2317
DOI:10.1016/j.redox.2024.103202